Figure 2.

SHP2 inhibitor II-B08 inhibits the constitutive growth of human leukemic mast cell line HMC1.2 and human CD34⁺ cells bearing KITD816V as well as primary BM-derived AML blasts. (A) Human leukemic mast cell line HMC 1.2 or (B) human CD34⁺ cells transduced with KITD816V were starved for 6 hours in serum- and cytokine-free media and treated with indicated amounts of SHP2 inhibitor II-B08. After 48 hours, proliferation was evaluated by [³H] thymidine incorporation. Bars represent the mean thymidine incorporation (CPM ± SD) from 1 independent experiment performed in quadruplicate. *P < .001.